The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Arnon NaglerDuring the EHA 2022 Congress, the GvHD Hub was pleased to speak to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How do you optimize donor selection for allogeneic transplant? Comparing MSD, UD, and haploidentical donors.
How to optimize donor selection for allogeneic transplant?
Nagler begins by comparing leukemia-free and relapse-free survival with different donor types, including sibling, unrelated, mismatched, and haploidentical donors. Nagler goes on to talk about incidence of chronic GvHD (cGvHD) in transplant, and factors to consider when selecting a donor. Finally, Nagler discusses how to prevent GvHD and infections.